Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.
Yahui ZhuJing ZhouLijing ZhuWenjing HuBaorui LiuLi XiePublished in: Human vaccines & immunotherapeutics (2022)
Cervical cancer is one of the most common malignancies among females. As a virus-related cancer, cervical cancer has attracted a lot of attention to develop virus-targeted immune therapy, including vaccine and adoptive immune cell therapy (ACT). Adoptive tumor infiltrating lymphocytes (TILs) cell therapy has been found to be able to control advanced disease progression in some cervical cancer patients who have received several lines of treatment in a pilot clinical trial. In addition, sustainable therapeutic effect has been identified in some cases. The safety risks of TIL therapy for patients are minimal or at least manageable. In this review, we focused on the versatility of TILs and tried to summarize potential strategies to improve the therapeutic effect of TILs and discuss related perspectives.
Keyphrases
- cell therapy
- stem cells
- mesenchymal stem cells
- clinical trial
- end stage renal disease
- peripheral blood
- chronic kidney disease
- newly diagnosed
- ejection fraction
- study protocol
- human health
- working memory
- peritoneal dialysis
- cancer therapy
- randomized controlled trial
- open label
- phase ii
- drug delivery
- young adults
- drug induced
- patient reported
- climate change